Latest Celosia Therapeutics News & Updates

See the latest news and media coverage for Celosia Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Celosia Therapeutics

Gene therapy developer for neurodegenerative diseases

celosiatx.com
Headquarters
Sydney, Australia
Founded year
2022
Company type
Private company
Number of employees
1–5

Last updated

Latest news about Celosia Therapeutics

In short: Celosia Therapeutics dosed the first patient in its Phase 1b clinical trial of CTx1000 for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Company announcements

  • Celosia Therapeutics

    Celosia Therapeutics doses first patient in Phase 1 study

    The study tests CTX 1000's safety and efficacy for ALS patients at Macquarie University Hospital. Professor Lars Ittner highlights this milestone after 17 years of development.

  • Celosia Therapeutics

    Celosia Therapeutics doses first patient in Phase 1b KOANEWA trial

    The trial evaluates CTx1000 gene therapy targeting TDP-43 in ALS patients at Macquarie University Hospital. CEO highlights milestone for ALS community.

  • Celosia Therapeutics

    Celosia secures second U.S. patent for CTx1000 therapy

    This strengthens IP foundation amid clinical preparation for first-in-human dosing. The team advances toward patient impact.

  • Celosia Therapeutics

    Celosia Therapeutics mourns Iomar Barrett's passing

    Iomar Barrett was a courageous ALS patient, visionary Series A investor, and steadfast supporter who shaped the company's foundation and mission for ALS therapies.

Unlock all announcements with a

Media coverage

Track future articles with a

Never miss news about Celosia Therapeutics

Track Celosia Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Celosia Therapeutics competitors & trending companies

Browse news for competitors to Celosia Therapeutics and other trending companies.